<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100162</url>
  </required_header>
  <id_info>
    <org_study_id>871/15</org_study_id>
    <nct_id>NCT03100162</nct_id>
  </id_info>
  <brief_title>Effect of Oral Supplementation With Probiotics</brief_title>
  <official_title>Effect of Oral Supplementation With Probiotics on Cardiometabolic Risk Factors, Microflora and Intestinal Epithelial Permeability, Mineral Content and Lifestyle in Obese Women With Postmenopausal Metabolic Syndrome: Double-blind, Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poznan University of Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poznan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of oral supplementation with probiotics on cardiometabolic risk factors, microflora&#xD;
      and intestinal epithelial permeability, mineral content and lifestyle in obese women with&#xD;
      postmenopausal metabolic syndrome: double-blind, randomized clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to determine whether oral probiotic supplementation affects&#xD;
      cardiometabolic risk, intestinal epithelial permeability, metabolic activity and intestinal&#xD;
      flora composition, mineral content, and lifestyle in obese women with metabolic syndrome.&#xD;
&#xD;
      Probiotics are a group of non-pathogenic microbes that bring health benefits to the host.&#xD;
      Their use enables the variety and proper functioning of intestinal microflora. The use of&#xD;
      probiotics increases the amount of bifidobacteria and lactobacilli, what directly affects the&#xD;
      reduction of endotoxemia by sealing the intestinal wall, as well as the improvement of fat,&#xD;
      carbohydrate and insulin metabolism.&#xD;
&#xD;
      The project is due to evaluate the effect of supplementation with selected probiotics in&#xD;
      patients with metabolic syndrome on:&#xD;
&#xD;
        -  lipid metabolism- total cholesterol, HDL and LDL cholesterol and triglycerides,&#xD;
&#xD;
        -  blood glucose concentration,&#xD;
&#xD;
        -  blood pressure values,&#xD;
&#xD;
        -  anthropometric parameters,&#xD;
&#xD;
        -  quality of life,&#xD;
&#xD;
        -  the contentl of minerals,&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 27, 2016</start_date>
  <completion_date type="Actual">February 2, 2018</completion_date>
  <primary_completion_date type="Actual">January 4, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with decreased cardiometabolic risk</measure>
    <time_frame>At the baseline and after 3 months of treatment</time_frame>
    <description>Cardiometabolic risk will be estimated at baseline and after 3 months of treatment using the SCORE scale. SCORE scale summarize 5 risk factors (sex, age, systolic blood pressure, total cholesterol and smoking). The number of patients with decreased cardiometabolic risk will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>At the baseline and following 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>At the baseline and following 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>At the baseline and following 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum lipids</measure>
    <time_frame>At the baseline and following 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total antioxidant status (TAS) evaluated by colorimetric method with Tas Randox kit</measure>
    <time_frame>At the baseline and following 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin estimated by immunoassay (DIAsource immunoassays)</measure>
    <time_frame>At the baseline and following 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interleukin-6 measured by an enzyme-linked immunosorbent assay (R&amp;D Quantikine® Human Il-6 kit)</measure>
    <time_frame>At the baseline and following 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body fat content</measure>
    <time_frame>At the baseline and following 3 months of treatment</time_frame>
    <description>Total body fat content will be measured at baseline and after 3 months of treatment using electrical bioimpedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of mineral content in hair</measure>
    <time_frame>At the baseline and following 3 months of treatment</time_frame>
    <description>The content of iron, magnezium, calcium, selenium, copper and lead in patients' hair at baseline and after 3 months of treatment will be estimated using atomic absorption spectrometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal examination (Kalprotektyna, Alfa1 - antytrypsyna )</measure>
    <time_frame>At the baseline and following 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At the baseline and following 3 months of treatment</time_frame>
    <description>&quot;The World Health Organization Quality of Life (WHOQOL) - BREF&quot;</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals receive a placebo daily, for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic 2g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals receive 2 g of probiotic daily, for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic 4g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals receive 4 g of probiotic daily, for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <arm_group_label>Probiotic 2g</arm_group_label>
    <arm_group_label>Probiotic 4g</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  body mass index (BMI) equal to or greater than 30 kg/m2&#xD;
&#xD;
          -  age 45 to 70 years&#xD;
&#xD;
          -  stable body weight (&lt; 3 kg self-reported change during the previous three months)&#xD;
&#xD;
          -  written informed consent to participate in the study,&#xD;
&#xD;
          -  &gt; = 1 year after the last menstrual period;&#xD;
&#xD;
          -  abdominal obesity - waist circumference&gt; 80 cm;&#xD;
&#xD;
          -  body fat content measured by bio-impedance ≥ 33%;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  secondary obesity or secondary hypertension&#xD;
&#xD;
          -  diabetes type I&#xD;
&#xD;
          -  gastrointestinal disease;&#xD;
&#xD;
          -  dyslipidaemia, type 2 diabetes, hypertension requiring the implementation of&#xD;
             pharmacological treatment in the last 3 months prior to observation or follow-up;&#xD;
&#xD;
          -  a history of use of any dietary supplements within the one month prior to the study&#xD;
&#xD;
          -  taking antibiotics within 1 month before starting the study;&#xD;
&#xD;
          -  Clinically relevant acute or chronic inflammatory disease in the respiratory,&#xD;
             gastrointestinal or genitourinary system or in the mouth, throat, paranasal sinuses&#xD;
             and / or connective tissue disease, arthritis;&#xD;
&#xD;
          -  simultaneous participation in a study that affects weight change or use of diet /&#xD;
             medication / nutritional behaviors affecting body weight changes;&#xD;
&#xD;
          -  consumption of pre- and probiotic-enriched products (for at least 3 weeks prior to the&#xD;
             first screening visit) and products with high fiber content or large amounts of&#xD;
             fermented foods (&gt; 400g / day);&#xD;
&#xD;
          -  hormone replacement therapy;&#xD;
&#xD;
          -  a history of infection in the month prior to the study&#xD;
&#xD;
          -  nicotine, drug or alcohol abuse&#xD;
&#xD;
          -  vegetarian diet;&#xD;
&#xD;
          -  or other condition that, in the opinion of the investigators, would make participation&#xD;
             not in the best interest of the patient or could prevent, limit, or confound the study&#xD;
             results&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pawel Bogdanski, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poznan University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Education and Obesity Treatment and Metabolic Disorders, Poznan University of Medical Sciences</name>
      <address>
        <city>Poznan</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Pawel Bogdanski</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>probiotics</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>obesity</keyword>
  <keyword>microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

